Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

The Lancet Respiratory Medicine

Volumn 3, Issue 8, 2015, Pages 631-639

  Chen, Wenjia ^a   Thomas, Jamie ^a   Sadatsafavi, Mohsen ^a   FitzGerald, J Mark ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG CIRCULATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW; AGED; CARDIOVASCULAR DISEASES; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; ODDS RATIO; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS;

EID: 84939464236     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00241-6     Document Type: Article

References (57)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
3. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010, 7:214-228.
4. Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011, 11:612.
5. Soriano JB, Lamprecht B Chronic obstructive pulmonary disease: a worldwide problem. Med Clin North Am 2012, 96:671-680.
6. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. the ATS/ERS Task Force.
7. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007, 14(suppl B):5B-32B.
8. Patel ARC, Hurst JR Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011, 5:647-662.
9. Wood-Baker R, Cochrane B, Naughton MT Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J 2010, 40:94-101.
10. Agusti A, Soriano JB COPD as a systemic disease. COPD 2008, 5:133-138.
11. Müllerova H, Agusti A, Erqou S, Mapel DW Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013, 144:1163-1178.
12. The PRISMA statement PRISMA, (accessed Aug 5, 2014). http://www.prisma-statement.org/statement.htm.
13. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
14. Miller RG The jackknife-a review. Biometrika 1974, 61:1-15.
15. Thompson SG, Higgins JPT How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21:1559-1573.
16. Sterne JA, Egger M Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001, 54:1046-1055.
17. Agarwal S, Rokadia H, Senn T, Menon V Burden of cardiovascular disease in chronic obstructive pulmonary disease. Am J Prev Med 2014, 47:105-114.
18. Albu A, Fodor D, Bondor C, Suciu O Carotid arterial stiffness in patients with chronic obstructive pulmonary disease. Acta Physiol Hung 2011, 98:117-127.
19. Antonelli-Incalzi R, Imperiale C, Bellia V, et al. Do GOLD stages of COPD severity really correspond to differences in health status?. Eur Respir J 2003, 22:444-449. the SaRA Investigators.
20. Antonelli-Incalzi R, Pedone C, Scarlata S, et al. Correlates of mortality in elderly COPD patients: focus on health-related quality of life. Respirology 2009, 14:98-104.
21. Baty F, Putora PM, Isenring B, Blum T, Brutsche M Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013, 8:e63285.
22. Bentsen SB, Rustøen T, Miaskowski C Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. J Pain 2011, 12:539-545.
23. Blanchette CM, Roberts MH, Petersen H, Dalal AA, Mapel DW Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis 2011, 6:73-81.
24. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:112-119.
25. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
26. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010, 65:956-962.
27. Finkelstein J, Cha E, Scharf SM Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009, 4:337-349.
28. García-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011, 139:1072-1080.
29. Holguin F, Folch E, Redd SC, Mannino DM Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005, 128:2005-2011.
30. Kollert F, Müller C, Tippelt A, et al. Anaemia in chronic respiratory failure. Int J Clin Pract 2011, 65:479-486.
31. Konecny T, Park JY, Somers KR, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014, 114:272-277.
32. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS Cardiovascular morbidity in COPD: A study of the general population. COPD 2010, 7:5-10.
33. Lin P-J, Shaya FT, Scharf SM Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010, 104:697-704.
34. Lindberg A, Larsson L-G, Rönmark E, Lundbäck B Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD 2011, 8:421-428.
35. Mannino DM, Thorn D, Swensen A, Holguin F Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
36. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000, 117(suppl 2):346S-353S.
37. Mapel DW, Dedrick D, Davis K Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005, 2:35-41.
38. Miniati M, Monti S, Pavlickova I, Bottai M Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) 2014, 93:e76.
39. Schneider C, Bothner U, Jick SS, Meier CR Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010, 25:253-260.
40. Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
41. Sin DD, Man SFP Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
42. Sode BF, Dahl M, Nordestgaard BG Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011, 32:2365-2375.
43. van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schadé E Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001, 54:287-293.
44. Buch P, Friberg J, Scharling H, Lange P, Prescott E Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003, 21:1012-1016.
45. Amabile CM, Spencer AP Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004, 164:709-720.
46. Manson SC, Brown RE, Cerulli A, Vidaurre CF The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009, 103:975-994.
47. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010, 137:13-19.
48. Angermann CE Comorbidities in heart failure: a key issue. Eur J Heart Fail Suppl 2009, 8:i5-10.
49. Damman K, Maass AH, van der Meer P Heart failure highlights in 2010. Eur J Heart Fail 2011, 13:358-363.
50. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010, 160:95-101.
51. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013, 36:3009-3014.
52. Ställberg B, Janson C, Johansson G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J 2014, 23:38-45.
53. Ruel G, Lévesque J-F, Stocks N, et al. Understanding the evolution of multimorbidity: evidences from the North West Adelaide Health Longitudinal Study (NWAHS). PLoS One 2014, 9:e96291.
54. Van Eeden S, Leipsic J, Paul Man SF, Sin DD The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med 2012, 186:11-16.
55. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014, 370:2191-2200. the National Heart, LungLung, Blood Institute ARDS Clinical Trials NetworkBlood Institute ARDS Clinical Trials Network.
56. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014, 370:2201-2210. the COPD Clinical Research Network, the Canadian Institutes of Health Researchthe Canadian Institutes of Health Research.
57. Du Q, Sun Y, Ding N, Lu L, Chen Y Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One 2014, 9:e113048.